Pharmaceutical API Company Valiant Laboratories files DRHP with SEBI for the proposed IPO; Key Details here

Valiant Laboratories is into Healthcare & Pharmaceuticals Pharmaceutical API and is looking raise funds through Fresh Issue

Valiant Laboratories to raise Fresh Issue of Equity shares up to 11,556,000 and an Offer for Sale Equity shares aggregating up to Rs. crores IPO

Valiant Laboratories IPO: Valiant Laboratories Limited has filed Draft Red Herring Prospectus (DRHP) for proposed initial public offer (IPO) and raise funds through an offer of equity share capital having face value of Rs. 10 per share via initial public offering.

Initial Public Offer comprising of a Fresh Issue aggregating up to 11,556,000 Equity Shares. Unistone Capital have been appointed as lead merchant bankers for the proposed IPO. It has appointed Link Intime India Pvt. Ltd. as Registrar and Share transfer Agent. Company is yet to finalize issue size and some other important details relating to the IPO.

Details about upcoming IPO:
As per the details available in DRHP, fundraising will consist of an Fresh Issue of up to 11,556,000 Equity Sharesby IPO Issue compreses of Fresh Issue hence, no selling shareholders...

Objects of the issue:
1) Investment in VASPL (wholly owned subsidiary, Valiant Advanced Sciences Private Limited) for part-financing its capital expenditure requirements in relation to the setting up of the Proposed Facility amounting to Rs. 80 cr , 2) Investment in VASPL for funding its working capital requirements amounting to Rs. 45 cr, and 3) General corporate purpose.

Promoters of Valiant Laboratories are Shantilal Shivji Voraand Dhanvallabh Ventures LLP and holds 100% stake in the company.

About Company:
Company established in 1980 is into Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing having focus on manufacturing of Paracetamol. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. Paracetamol (Scientific name: Acetaminophen or para-hydroxyacetanilide -C8H9NO2), is one of the most commonly taken analgesic worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO). Company manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of our customers. It has 3 top group companies - Aarti Industries, Aarti Pharmalabs and Valiant Organics.

About Industry:
The pharmaceutical API industry in India is ranked third-largest globally in terms of volume. The paracetamol API industry (Domestic consumption+ exports) grew from Rs. 22 billion in fiscal 2017 to Rs. 39 billion in fiscal 2023. Going forward the paracetamol API industry is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well asexportmarkets.

Source: SEBI, BSE, NSE, DRHP, Valiant Laboratories, Industry Data

Disclaimer: Above article only publishes details about the IPO for educational purpose and doesn't solicit or invite any interest to invest. Please visit respective sources to verify and know more details about the IPO. We advise investors to take opinion from certified/SEBI registered experts before taking any investment decisions.